Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Cardiovascular > CV pharmacology > Flashcards

CV pharmacology Flashcards

(60 cards)

Start Studying
1
Q

relationship between cardiac AP and ion channel currents

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Arrhythmias are caused by ?

A

abnormal pacemaker activity
abnormal impulse propagation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

The aim of therapy of the arrhythmias is to ?

A

reduce ectopic pacemaker activity
modify conduction or refractoriness in reentry circuits to disable circus movement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what do antiarrhythmic drugs do?

A
  • decrease automaticity of ectopic pacemakers more than that of SA node
  • reduce conduction and excitability and increase refractory period
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

3 subclasses are further defined by the effect of the agents on the Purkinje fiber AP:

class I

A
  • Class Ia: slow rate of rise of AP and prolong duration = slowing conduction and increasing refractoriness (moderate depression of phase 0 upstroke of the action potential)
  • Class Ib: shorten AP duration; do not affect conduction or refractoriness (minimal depression of phase 0 upstroke of AP)
  • Class Ic: Dissociates from channel with slow kinetics (no change in AP duration)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the drug classification for antiarrhythmics

A

Vaughan-Williams Classification system

  • Block fast Na channels (class I)
  • BB (class II)
  • block K channels (class III)
  • CCB (class IV)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what drugs are class Ia?

A

quinidine, procainamide, disopyramide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what drugs are class Ib?

A

lidocaine, mexiletine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what drugs are class Ic?

A

flecainide, propafenone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Quinidine MOA/effect

A
  1. potent anticholinergic properties that affect SA and AV nodes = increase SA nodal discharge rate and AV nodal conduction
    - may lead to increased ventricular rates with afib or aflutter
    - Addition of BB, non-dihydropyridine CCB, or digoxin protects against this
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

SE of Quinidine

A

GI-related - N/V/D
Proarrhythmic – torsades
Can interact with CYP3A4 inducers or inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

difference between Quinidine vs Procainamide

A

Does not have the anticholinergic activity of quinidine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

SE of procainamide

A
  • Prolongs QT interval = risk of torsades
  • SLE – MC adverse event
  • N/V/D and drug fever
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

disopyramide effect

A

Potent anticholinergic and negative inotropic effects limits uses clinically

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

SE/CI of disopyramide

A
  • Prolongs QT = torsades
  • CI: reduced LV EF (<40%)
  • Precipitation of CHF
  • Anticholinergic effects – dry mouth, urinary retention, constipation, blurred vision
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

lidocaine effect

A
  • Selective to ischemic tissue, and esp to active fast Na channels in bundle of HIS, Purkinje fibers, and ventricular myocardium
  • Primarily effective in treating ventricular dysrhythmias, especially those associated with acute MI
  • Little effect: non-ischemic tissue, atrial myocardium, and automaticity of the SA node
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

monitoring for lidocaine

A

Cleared by hepatic metabolism, therefore, monitor closely for signs of toxicity in patients with liver failure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

SE of lidocaine

A

CNS effects of dizziness, paresthesia, disorientation, tremor, agitation, seizures and respiratory arrest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

effect of mexiletine

A
  • Not used as a single agent - combo w/ class IA and III drugs for the tx of refractory ventricular dysrhythmias
  • Similar to lidocaine, but in oral form
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

SE mexiletine

A
  • GI – N/V, limits use
  • neurologic - dizziness, confusion, ataxia, and speech disturbances
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

MOA of Flecainide (Tambacor)

A
  • Slows conduction velocity in Purkinje fibers & AV node
  • lengthen PR interval & QRS duration
  • MC for afib/flutter
  • for VT but it sucks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

SE of flecainide

A
  • Rapid VT, resistant to resuscitation, esp with CAD, LV dysfunction, LVH or valvular disease - AVOID in any heart dz
  • Blurred vision, dizziness, HA, tremor, N/V
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

MOA of propafenone

A
  • Class IC
  • Slows conduction velocity in Purkinje fibers and AV node; also has a mild nonselective BB effect
  • lengthen PR interval and QRS duration = conduction disturbances (bradycardia, blocks)
  • MC for afib/flutter
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

SE of propafenone

A
  • May cause VT similar to flecainide, so avoid in any form of heart dz
  • Blurred vision, dizziness, HA, N/V, bronchospasm, and taste disturbances (metallic taste)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
MOA of BB
* Decrease automaticity, prolong AV conduction, and prolong refractoriness - Negative chronotropic and inotropic effects * Suppresses ventricular dysrhythmias + supraventricular dysrhythmias * esp helpful when used in combination with other AAD * _Metoprolol MC_
26
which BB can be used as a continuous IV infusion for rapid afib/flutter
esmolol
27
MOA of class III AAD
* Block K channels and prolong repolarization, widening QRS and prolonging QT interval. * Decrease automaticity and conduction and prolong refractoriness.
28
Avoid concomitant use of class III AADs with ?
other drugs that can prolong QT interval to minimize the risk of torsades
29
MOA of amiodarone
1. Possesses characteristics of all 4 classes - Primarily K channel blocker, also blocks Na channels, has non-selective BB activity, weak CCB properties - Works on all cardiac cells (SA node, AV node, atria, ventricles and Purkinjes) 2. Minimal/no negative inotropic effects - Can be used w/ LV dysfunction
30
SE of amiodarone
* Has potential to for its metabolite to accumulate and cause adverse effects in numerous organs, including the lungs, thyroid, eyes, heart, liver, skin, GI tract, and nervous system * GI common - N/V, anorexia, abd pain (take w/ food) * Neurologic toxicities occur frequently - Tremors, ataxia, peripheral neuropathy, fatigue and insomnia * Liver toxicity is rare, but screening LFTs Q6 mo * Derm - photosensitivity, blue/gray discoloration - Sunscreen + sun exposure avoidance to help
31
amiodarone is a potent inhibitor of what enzyme?
CYP3A4 * Many DDI * Potentiates the anticoagulation effects of warfarin; close monitoring is essential * Can double serum digoxin concentrations
32
MOA of sotalol
1. Class III that also has **nonselective beta-adrenergic blocking properties** - May decrease cardiac contractility and therefore should be avoided in patients with LV dysfunction 2. **Prolongs atrial and ventricular refractoriness**
33
SE of sotalol
1. QT prolongation common - monitored for closely - DC if QT interval > 550 ms - Avoid combining with other QT prolonging drugs 2. Most SE from BB properties
34
MOA of dofetilide
Results in prolonged AP and an increased QT interval * Affects atria > ventricles * No negative inotropic effects = safe in LV dysfunction
35
SE of dofetilide
**torsades de pointes** - Admit, telemetry Q12 hr EKG’s for first 3 days of loading to monitor QT interval and adjust dose
36
CI with dofetilide
* Cimetidine, ketoconazole, megestrol, prochlorperazine, Bactrim, or verapamil - Avoid inhibitors of the CYP3A4 isoenzyme * Renally cleared, avoid if CrCl < 20 mL/min
37
MOA of dronedarone
* Exact MOA unknown; exhibits AA properties of all 4 classes * Some considered it the “safe cousin of amiodarone”; but not nearly as effective, and side effects and toxicities are still common
38
SE of dronedarone
CHF exacerbation QT prolongation bradycardia hepatotoxicity pulmonary toxicity photosensitivity N/D pruritis dyspepsia
39
CI of dronedarone
* Symptomatic CHF & recent decompensation requiring hospitalization * Permanent AF * Severe hepatic impairment
40
monitoring for dronedarone
BUN/Cr; EKG q 3 mos; LFT’s during 1st 6 mos of Tx
41
effect and indication for ibutilide
Ibutilide - Corvert * Structurally similar to sotalol, but _no BBing activity_ * IV only, and indicated only for **afib/flutter cardioversion**
42
SE of ibutilide
**torsades** * Monitored on telemetry following IV infusion * _Avoid_: LV dysfunction and electrolyte abnormalities (esp hypokalemia and hypomagnesemia)
43
verapamil
CCB
44
diltiazem
CCB
45
MOA of CCB
* Decrease automaticity and AV conduction * Potent negative inotropic effects - **avoid LV dysfunction**
46
MOA of digoxin
Predominant AA effect is on AV node * Inhibits Ca currents in AV node and activates Ach-mediated K+ currents in atrium * Slows conduction thru AV node and prolongs AV nodal refractory period * Therefore, mainly used for **slowing the ventricular rate in afib/flutter**, as well as **terminating reentrant arrhythmias involving AV node**
47
On EKG you see PR prolongation and ST segment depression, what is going on?
digoxin effect
48
toxicity of digoxin is a risk if ____ are administered that destroy intestinal microflora
antibiotics
49
PK of digoxin
* Half-life - 36 hrs = **once daily** dosing * **Renal elimination** = reduced dose/dosing intervals with renal insufficiency * IV or oral - Tablets are incompletely bioavailable * **intestinal microflora may metabolize digoxin** = reduced bioavailability = need higher doses * **Slow distribution** to effector sites - Even w/ IV * Requires loading dose 0.6-1 mg x 24 hrs, then reduce to maintenance dose
50
what drugs specific can decrease digoxin clearance?
Amiodarone quinidine verapamil diltiazem itraconazole propafenone flecainide dose should be decreased if combining with these drugs
51
signs of digoxin toxicity?
* declining renal function, electrolyte abnormalities, hypoxia or DDI * Visual disturbances, dizziness, weakness, N/V/D, anorexia * Essentially ANY dysrhythmia can result from digoxin toxicity
52
tx of digoxin toxicity
* IV hydration and electrolyte correction * **Digoxin immune Fab** - an immunoglobulin fragment with specific and high affinity for digoxin molecules
53
MOA of adenosine
* Activates K channels and by increasing outward K current hyperpolarizes the membrane potential, decreasing spontaneous SA nodal depolarization * Inhibits automaticity and conduction in the SA and AV nodes
54
adenosine is used for converting what abnormality to sinus rhythm?
SVT to sinus rhythm; essentially causing sinus arrest
55
SE of adenosine
Chest discomfort, dyspnea, flushing, HA
56
what is atropine
* _Parasympatholytic_ drug that **enhances both sinus nodal automaticity & AV nodal** conduction through direct vagolytic action * Blocks Ach at parasympathetic neuroeffector sites
57
when is atropine used?
emergent setting of symptomatic bradycardia
58
SE of atropine
* **tachycardia** - may result in poor outcomes in pts with MI, so use cautiously * **paradoxical slowing HR** with Mobitz type II AVB and 3rd degree AVB - monitor
59
which AADs are **safe for LV dysfunction**
1. amiodarone 2. dofetilide
60
which AADs should be avoided in LV dysfunction
1. Flecainide 1. sotalol 1. ibutilide 1. CCB

Cardiovascular (24 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions